How i treat and manage strokes in sickle cell disease

Blood

Volumn 125, Issue 22, 2015, Pages 3401-3410

  Kassim, Adetola A ^a   Galadanci, Najibah A ^b   Pruthi, Sumit ^a   DeBaun, Michael R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYERO UNIVERSITY   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BRAIN INFARCTION; CASE REPORT; CEREBROVASCULAR ACCIDENT; COGNITIVE REHABILITATION; DOPPLER ECHOGRAPHY; EXCHANGE BLOOD TRANSFUSION; FEMALE; HEMATOLOGIST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MORBIDITY; MORTALITY; NEUROIMAGING; NEUROLOGICAL COMPLICATION; NEUROLOGIST; NEURORADIOLOGIST; PREVALENCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STROKE PATIENT; TRANSFUSION MEDICINE; ANEMIA, SICKLE CELL; COMPLICATION; DIFFERENTIAL DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; STROKE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; STROKE;

EID: 84930941121     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-551564     Document Type: Article

References (89)

1. Sydentricked VP, Mulherin WA, Houseal RW. Sickle cell anemia: report of two cases in children with necropsy in one case. Am J Dis Child. 1923; 26(2):132-154.
2. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461-471.
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
4. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236.
5. Easton JD, Saver JL, Albers GW, et al; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-2293.
6. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42(5):699-704.
7. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3): 772-779.
8. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014; 371(8):699-710.
9. Momjian-Mayor I, Baron JC. The pathophysiology of watershed infarction in internal carotid artery disease: review of cerebral perfusion studies. Stroke. 2005;36(3):567-577.
10. Anson JA, Koshy M, Ferguson L, Crowell RM. Subarachnoid hemorrhage in sickle-cell disease. J Neurosurg. 1991;75(4):552-558.
11. Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J Neurosurg. 1991;75(3):356-363.
12. Kossorotoff M, Brousse V, Grevent D, et al. Cerebral haemorrhagic risk in children with sicklecell disease. Dev Med Child Neurol. 2015;57(2): 187-193.
13. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics. 2006;118(5):1916-1924.
14. Diggs LW, Brookoff D. Multiple cerebral aneurysms in patients with sickle cell disease. South Med J. 1993;86(4):377-379.
15. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9): 3144-3150.
16. Powars D, Adams RJ, Nichols FT, Milner P, Charache S, Sarnaik S. Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. J Assoc Acad Minor Phys. 1990;1(3): 79-82.
17. Royal JE, Seeler RA. Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions. Lancet. 1978; 2(8101):1207.
18. Prengler M, Pavlakis SG, Boyd S, et al. Sickle cell disease: ischemia and seizures. Ann Neurol. 2005;58(2):290-302.
19. Liu JE, Gzesh DJ, Ballas SK. The spectrum of epilepsy in sickle cell anemia. J Neurol Sci. 1994; 123(1-2):6-10.
20. Palermo TM, Platt-Houston C, Kiska RE, Berman B. Headache symptoms in pediatric sickle cell patients. J Pediatr Hematol Oncol. 2005;27(8): 420-424.
21. Niebanck AE, Pollock AN, Smith-Whitley K, et al. Headache in children with sickle cell disease: prevalence and associated factors. J Pediatr. 2007;151(1):67-72,e61.
22. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3): 543-552.
23. Jen JC, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch Neurol. 2004;61(6):926-928.
24. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366(9483):371-377.
25. Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007;130(pt 2):346-356.
26. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
27. Henderson JN, Noetzel MJ, McKinstry RC, White DA, Armstrong M, DeBaun MR. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood. 2003;101(2):415-419.
28. Lucchini G, Grioni D, Colombini A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51(5):629-633.
29. Moon SN, Jeon SJ, Choi SS, et al. Can clinical and MRI findings predict the prognosis of variant and classical type of posterior reversible encephalopathy syndrome (PRES)? Acta Radiol. 2013;54(10):1182-1190.
30. Donmez FY, Guleryuz P, Agildere M. MRI findings in childhood PRES: what is different than the adults? [published online ahead of print October 8, 2014]. Clin Neuroradiol.
31. Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology. 2001; 219(3):756-765.
32. Provenzale JM, Engelter ST, Petrella JR, Smith JS, MacFall JR. Use of MR exponential diffusion-weighted images to eradicate T2 "shine-through" effect. AJR Am J Roentgenol. 1999;172(2): 537-539.
33. van Mierlo TD, van den Berg HM, Nievelstein RA, Braun KP. An unconscious girl with sickle-cell disease. Lancet. 2003;361(9352):136.
34. Oʇuz M, Aksungur EH, Soyupak SK, Yildirim AU. Vein of Galen and sinus thrombosis with bilateral thalamic infarcts in sickle cell anaemia: CT follow-up and angiographic demonstration. Neuroradiology. 1994;36(2):155-156.
35. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158-1192.
36. Fiebach JB, Schellinger PD, Gass A, et al; Kompetenznetzwerk Schlaganfall B5. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke. 2004;35(2):502-506.
37. Lansberg MG, Albers GW, Beaulieu C, Marks MP. Comparison of diffusion-weighted MRI and CT in acute stroke. Neurology. 2000;54(8):1557-1561.
38. Muir KW, Buchan A, von Kummer R, Rother J, Baron JC. Imaging of acute stroke. Lancet Neurol. 2006;5(9):755-768.
39. Schlaug G, Siewert B, Benfield A, Edelman RR, Warach S. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology. 1997;49(1):113-119.
40. Dowling MM, Quinn CT, Rogers ZR, Buchanan GR. Acute silent cerebral infarction in children with sickle cell anemia. Pediatr Blood Cancer. 2010;54(3):461-464.
41. Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992;120(6): 882-885.
42. Oppenheim C, Stanescu R, Dormont D, et al. False-negative diffusion-weighted MR findings in acute ischemic stroke. AJNR Am J Neuroradiol. 2000;21(8):1434-1440.
43. Sylaja PN, Coutts SB, Krol A, Hill MD, Demchuk AM; VISION Study Group. When to expect negative diffusion-weighted images in stroke and transient ischemic attack. Stroke. 2008;39(6): 1898-1900.
44. Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol. 1999;14(5):277-281.
45. Vichinsky EP, Neumayr LD, Earles AN, et al; National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
46. Hurlet-Jensen AM, Prohovnik I, Pavlakis SG, Piomelli S. Effects of total hemoglobin and hemoglobin S concentration on cerebral blood flow during transfusion therapy to prevent stroke in sickle cell disease. Stroke. 1994;25(8): 1688-1692.
47. Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr. 2006;149(5): 710-712.
48. Hamdan JM, Mallouh AA, Ahmad MS. Hypertension and convulsions complicating sickle cell anaemia: possible role of transfusion. Ann Trop Paediatr. 1984;4(1):41-43.
49. Warth JA. Hypertension and a seizure following transfusion in an adult with sickle cell anemia. Arch Intern Med. 1984;144(3):607-608.
50. DeBaun MR. Secondary prevention of overt stroke in sickle cell disease: therapeutic strategies and efficacy. Hematology Am Soc Hematol Educ Program. 2011;2011:427-433.
51. Gueguen A, Mahevas M, Nzouakou R, et al. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. Am J Hematol. 2014;89(3):267-272.
52. Morgenstern LB, Hemphill JC III, Anderson C, et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108-2129.
53. Becker H, Desch H, Hacker H, Pencz A. CT fogging effect with ischemic cerebral infarcts. Neuroradiology. 1979;18(4):185-192.
54. Skriver EB, Olsen TS. Transient disappearance of cerebral infarcts on CT scan, the so-called fogging effect. Neuroradiology. 1981;22(2):61-65.
55. O'Brien P, Sellar RJ, Wardlaw JM. Fogging on T2-weighted MR after acute ischaemic stroke: how often might this occur and what are the implications? Neuroradiology. 2004;46(8): 635-641.
56. Dowling MM, Lee N, Quinn CT, et al. Prevalence of intracardiac shunting in children with sickle cell disease and stroke. J Pediatr. 2010;156(4): 645-650.
57. Razdan S, Strouse JJ, Naik R, et al. Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. Case Rep Hematol. 2013;2013:516705.
58. Lindsey T, Watts-Tate N, Southwood E, et al. Chronic blood transfusion therapy practices to treat strokes in children with sickle cell disease. J Am Acad Nurse Pract. 2005;17(7):277-282.
59. Savage WJ, Reddoch S, Wolfe J, Casella JF. Partial manual exchange reduces iron accumulation during chronic red cell transfusions for sickle cell disease. J Pediatr Hematol Oncol. 2013;35(6):434-436.
60. Ware RE, Helms RW; SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.
61. Mirre E, Brousse V, Berteloot L, et al. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease. Eur J Haematol. 2010;84(3): 259-265.
62. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896-899.
63. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002; 140(3):348-354.
64. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol. 2011;86(10): 846-850.
65. Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol. 2011;86(4):357-361.
66. Lagunju IA, Brown BJ, Sodeinde OO. Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. Niger Postgrad Med J. 2013;20(3):181-187.
67. Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 2002;71(3):161-165.
68. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
69. Walters MC, Hardy K, Edwards S, et al; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010; 16(2):263-272.
70. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1-6.
71. Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820-830.
72. Bernaudin F, Socie G, Kuentz M, et al; SFGM-TC. Long-term results of related myeloablative stemcell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756.
73. Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-352.
74. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012; 18(8):1265-1272.
75. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-4291.
76. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465.
77. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
78. Meloni A, Puliyel M, Pepe A, Berdoukas V, Coates TD, Wood JC. Cardiac iron overload in sickle-cell disease. Am J Hematol. 2014;89(7): 678-683.
79. Kaushik N, Eckrich MJ, Parra D, Yang E. Chronically transfused pediatric sickle cell patients are protected from cardiac iron overload. Pediatr Hematol Oncol. 2012;29(3):254-260.
80. Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica. 2013; 98(1):129-135.
81. Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014;53(3):164-167.
82. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95(4): 1229-1236.
83. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child. 1990; 144(5):565-569.
84. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992;339(8795): 699-701.
85. Kalpatthi R, Peters B, Kane I, et al. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Pediatr Blood Cancer. 2010; 55(7):1338-1342.
86. Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the doseresponse relationship. J Lab Clin Med. 1993; 122(1):48-54.
87. Office of Elementary and Secondary Education; Office of Special Education and Rehabilitative Services, U.S. Department of Education. Title I-improving the academic achievement of the disadvantaged; Individuals with Disabilities Education Act (IDEA)-assistance to states for the education of children with disabilities. Final regulations. Fed Regist. 2007;72(67): 17747-17781.
88. Wilimas J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96(2):205-208.
89. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118(3):377-382.